WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2008097596) NRF2 SCREENING ASSAYS AND RELATED METHODS AND COMPOSITIONS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2008/097596    International Application No.:    PCT/US2008/001602
Publication Date: 14.08.2008 International Filing Date: 07.02.2008
IPC:
G01N 33/68 (2006.01)
Applicants: BIOGEN IDEC MA INC. [US/US]; 14 Cambridge Center, Cambridge, MA 02142 (US) (For All Designated States Except US).
LUKASHEV, Matvey, E. [US/US]; (US) (For US Only)
Inventors: LUKASHEV, Matvey, E.; (US)
Agent: GARRETT, Arthur, S.; Finnegan, Henderson, Farabow, Garrett & Dunner L.L.P., 901 New York Avenue, NW, Washington, DC 0001-4413 (US)
Priority Data:
60/888,921 08.02.2007 US
Title (EN) NRF2 SCREENING ASSAYS AND RELATED METHODS AND COMPOSITIONS
(FR) ESSAIS DE CRIBLAGE DE NRF2 ET PROCÉDÉS ET COMPOSITIONS CORRESPONDANTS
Abstract: front page image
(EN)Provided are certain methods of screening, identifying, and evaluating neuroprotective compounds useful for treatment of neurological diseases, such as, e.g., multiple sclerosis (MS). The compounds described upregulate the cellular cytoprotective pathway regulated by Nrf2. Also provided are certain methods of utilizing such compounds in therapy for neurological disease, particularly, for slowing or reducing demyelination, axonal loss, or neuronal and oligodendrocyte death.
(FR)La présente invention concerne certains procédés de criblage, d'identification et d'évaluation de composés neuroprotecteurs utilisés dans le traitement de maladies neurologiques, telles qu'une sclérose en plaques. Les composés selon cette invention régulent positivement la voie cytoprotectrice des cellules qui est régulée par Nrf2. Cette invention concerne également certains procédés d'utilisation de tels composés dans le traitement de maladies neurologiques, notamment pour ralentir ou réduire la démyélinisation, la perte axonale ou la mort de neurones et d'oligodendrocytes.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)